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See Editorial, pages 768–769Background & Aims: Recently, spatial-temporal/metabolic from damaged hepatocytes into the blood where it consumes
mathematical models have been established that allow the sim- ammonia to generate glutamate, thereby providing systemic
ulation of metabolic processes in tissues. We applied these mod-
els to decipher ammonia detoxification mechanisms in the liver.
Methods: An integrated metabolic-spatial-temporal model was
used to generate hypotheses of ammonia metabolism. Predicted
mechanisms were validated using time-resolved analyses of
nitrogen metabolism, activity analyses, immunostaining and
gene expression after induction of liver damage in mice.
Moreover, blood from the portal vein, liver vein and mixed
venous blood was analyzed in a time dependent manner.
Results:Modeling revealed an underestimation of ammonia con-
sumption after liver damage when only the currently established
mechanisms of ammonia detoxification were simulated. By itera-
tive cycles of modeling and experiments, the reductive amidation
of alpha-ketoglutarate (a-KG) via glutamate dehydrogenase
(GDH) was identified as the lacking component. GDH is releasedJournal of Hepatology 20
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exploited therapeutically in a mouse model of hyperammonemia
by injectingGDH togetherwith optimizeddoses of cofactors. Intra-
venous injectionofGDH (720 U/kg),a-KG (280 mg/kg) andNADPH
(180 mg/kg) reduced the elevated blood ammonia concentrations
(>200 lM) to levels close to normal within only 15 min.
Conclusion: If successfully translated to patients the GDH-based
therapy might provide a less aggressive therapeutic alternative
for patients with severe hyperammonemia.
 2015 European Association for the Study of the Liver. Published
by Elsevier B.V. Open access under CC BY-NC-ND license.Introduction
Recent developments have strongly improved our capability to
generate information at multiple spatial and temporal scales
[1,2]. However, research on disease pathogenesis is hampered by
the difficulty to understand the orchestration of individual compo-
nents. Here, mathematical models help to formalize relations
between components, simulate their interplay, and to study pro-
cesses that are too complex to be understood intuitively [1]. This
is particularly important when studying the pathophysiology of
metabolic liver diseases, where due to zonation different meta-
bolic processes take place in pericentral and periportal hepato-
cytes [3]. To be able to investigate such complex processes we
recently established a technique of integrated metabolic spatial-
temporal modeling (IM) [4]. These IM integrate conventional
metabolic models into spatial-temporal models of the liver lobule
[1,4,5]. The present study was motivated by the IM predictions,
which proposed that the conventional mechanisms where16 vol. 64 j 860–871
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ammonia is metabolized by urea cycle enzymes in the periportal
compartments of the liver lobules and by glutamine synthetase
(GS) reaction in the pericentral compartments (Supplementary
Fig. 1) failed to explain the experimental findings [4]. The IM was
applied to an experimental scenario, where the entire pericentral
and a part of the periportal compartment of the liver lobules were
destroyed by a single high dose of the hepatotoxic compound car-
bon tetrachloride (CCl4). This leads to compromised nitrogen
metabolism and hyperammonemia. In the present study, we per-
formed a series of new experiments accompanied by simulations
with novel models to explore the mechanism responsible for the
observed discrepancy. Experimentally, the time-resolved analysis
of metabolites and metabolic activities after CCl4 intoxication
offers good conditions to study ammonia detoxification and possi-
ble compensatory mechanisms during the damage and regenera-
tion process. Time-resolved analysis of metabolites was
performed in the portal vein and heart blood, representing the
‘liver inflow’, and in the liver vein as ‘liver outflow’. These analyses
allowed a precise experimental validation of model predictions.
Finally, iterative cycles of modeling and experimental validation
allowed the identification of a so far unrecognized mechanism of
ammonia detoxification. Importantly, this mechanism could be
exploited therapeutically to reduce elevated blood ammonia con-
centrations close to normal levels by intravenous injection of glu-
tamate dehydrogenase (GDH; 720 U/kg) and its cofactors alpha-
ketoglutarate (a-KG; 280 mg/kg) as well as NADPH (180 mg/kg).
This example illustrates how concrete therapies can be derived
by model guided experimental strategies.Materials and methods
A detailed description of materials and methods is provided in the Supplemen-
tary materials. Male C57BL/6N 10–12 weeks old mice were used (Charles River,
Sulzfeld, Germany). Acute liver damage was induced by intraperitoneal injection
of 1.6 g/kg CCl4, unless other doses are indicated. Blood was taken from mice
under anesthesia from the portal and hepatic veins, as well as the right heart
chamber, and plasma was separated. Liver tissue samples were collected from
defined anatomical positions for histopathology, immunohistochemistry, enzyme
activity assays, gene array and qRT-PCR analyses. The dead cell area was quanti-
fied in hematoxylin and eosin stained tissue sections using Cell^M software
(Olympus, Hamburg, Germany). Whole-genome analysis of gene expression in
mouse liver tissue was performed in control as well as after CCl4 intoxication with
Affymetrix gene arrays. The latter techniques are described fully in the Supple-
mentary materials and methods. The analysis of ammonia and further metabo-
lites was performed using commercially available kits. Concentrations of amino
acids and organic acids in liver tissue were measured in duplicate using GC-MS.
GS, GDH and transaminases activity assays were performed photometrically as
described in the Supplementary materials and methods. NADP+ and NADPH were
analyzed by LC-MS. Mouse hepatocytes were isolated by a two-step EGTA/colla-
genase perfusion technique and either used directly in suspension or cultivated in
collagen sandwiches (Supplementary materials and methods). For the mathemat-
ical modeling of ammonia and the related metabolites the integrated metabolic,
spatio-temporal model was applied [4,5]. In addition, the IM was replaced by a
set of novel models that include further reactions and the blood compartment
of the liver (Supplementary materials and methods). Statistical analysis was done
with SPSS software as described in the Supplementary materials.Results
An integrated spatial-temporal-metabolic model suggests a so far
unrecognized mechanism of ammonia detoxification
The detoxification process in healthy, damaged and regenerating
livers was simulated using a recently established integratedJournal of Hepatology 201metabolic IM [4]. To compare the simulated metabolite concen-
trations with the in vivo situation, an experiment was performed
in which blood was collected from the portal vein (representing
85% of the ‘liver inflow’), the heart (representing 15% of the ‘liver
inflow’), and the hepatic vein (representing the ‘liver outflow’) in
a time-resolved manner after CCl4 injection (Fig. 1A; Supplemen-
tary Fig. 2). The result shows that ammonia is detoxified during
its passage through the liver as illustrated by the difference in
ammonia concentrations between the portal vein and the hepatic
vein in the control mice (Fig. 1B). This detoxification process is
compromised after liver damage, particularly on days 1 and 2.
Surprisingly, the IM model predicted higher ammonia concentra-
tions than those experimentally observed, particularly on day 1
(Fig. 1C; see the video in the Supplementary data). Analyses of
heart blood demonstrate the contribution of the extrahepatic
compartment, which includes brain, muscles, kidneys and blood,
to ammonia detoxification between days 1 and 4 after the induc-
tion of liver damage. However, this extrahepatic contribution is
small compared to detoxification by the liver (Supplementary
Figs. 2–8). In addition to the time-resolved study, similar experi-
ments were also performed in a dose dependent manner on day 1
after CCl4 administration when the discrepancy between simu-
lated and measured ammonia was maximal. For this purpose,
doses ranging between 10.9 and 1600 mg/kg CCl4 were tested,
resulting in a concentration dependent increase in the dead cell
area, with only the highest dose causing damage to the entire
CYP2E1 positive pericentral region of the liver lobule (Fig. 1D;
Supplementary Fig. 9A, B). Destruction of the GS positive area
occurred in with doses ranging between 38.1 and 132.4 mg/kg
(Fig. 1D, E; Supplementary Fig. 9C); also CPS1 showed a dose
dependent decrease (Supplementary Fig. 9C) leading to
compromised ammonia metabolism (Supplementary Fig. 10).
Using the IM [4], we also observed a discrepancy between the
predicted and measured ammonia in the dose dependent study
(Fig. 1F).
To find an explanation for this discrepancy, we performed
time-resolved gene array analysis of mouse liver tissue after
CCl4 intoxication (Fig. 2A). Fuzzy clustering identified seven gene
clusters, which reflected time dependent gene expression alter-
ations [6]. Clusters 4 and 6 contained genes whose expression
was transiently repressed at early time points after CCl4 intoxica-
tion (Fig. 2B). Further bioinformatics analyses revealed an over
representation of nitrogen/ammonia metabolism KEGG and Gene
ontology terms of genes in cluster 4 (Fig. 2C, D). Genes relevant
for ammonia metabolism were further studied by qRT-PCR,
immunostaining and activity assays. GS is the key enzyme for
ammonia detoxification in the pericentral compartment. RNA
levels of GS started to decrease as early as 6 h after CCl4 injection,
it was at its lowest between days 1 and 4, before finally recover-
ing to initial levels between days 6 and 30 (Fig. 2E). A similar
time-dependent curve was obtained for GS activity although
the decrease occurred slightly later than that of RNA with very
low levels between days 2 and 4 (Fig. 2E). The pattern and inten-
sity of GS immunostaining was found to be comparable to GS
activity (Fig. 2F). In addition, ornithine aminotransferase (OAT),
an enzyme exclusively localized in GS positive pericentral hepa-
tocytes that provides additional glutamate for fixing ammonia
[7], decreased to almost undetectable levels with a delayed
recovery (Supplementary Fig. 3A). The key enzymes of the peri-
portal compartment, CPS1, ASS1, ASL and arginase1 were simi-
larly analyzed in the same tissue (Supplementary Figs. 3B and6 vol. 64 j 860–871 861
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4). Extending the IM [4], with time-dependent enzyme concen-
trations (model 1), did not remove the discrepancy between
model predictions and experimental data (Supplementary
Fig. 11), indicating that our model lacks a relevant, but so far
unrecognized mechanism of ammonia detoxification.Heart
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using plasma from mice after CCl4 injection (Fig. 3A). Most of the
analyzed factors in plasma (urea, glutamine, glucose, lactate,
pyruvate, alanine, arginine and other amino acids: Supplemen-
tary Figs. 4–6) were as expected except for a-KG, which dramat-
ically decreased between 12 h and day 2 (Fig. 3A). This decrease
was accompanied by an almost concurrent increase in glutamate
levels, which persisted longer than the drop in a-KG. One poten-
tial explanation is the delayed recovery of GS, which uses gluta-
mate and ammonia to form glutamine (Fig. 2E, F). The decrease in
a-KG (and the increase in glutamate) was also accompanied by
increased GDH activity in plasma, because GDH is released from
damaged hepatocytes (Fig. 3A). The present observations suggest
that GDH released from the damaged hepatocytes into the blood
catalyzes, at least transiently, a reaction that consumes ammonia
to produce glutamate (Fig. 3D). To test this hypothesis, we col-
lected plasma from mice on day 1 after CCl4 injection. Addition
of a-KG alone was sufficient to slightly but significantly decrease
blood ammonia concentrations (Fig. 3B). This decrease was
enhanced by further adding NADPH and particularly GDH;
whereas the GDH inhibitor, PDAC completely antagonized the
effect. To test also higher ammonia concentrations typically
observed in patients with severe pre-coma hyperammonemia,
600 lM ammonia was added to plasma collected on day 1 after
CCl4 administration. Under these conditions, a-KG also reduced
ammonia and increased glutamate concentrations (Fig. 3C; Sup-
plementary Fig. 12A). Together, these experiments suggest that
a GDH reaction consuming ammonia in blood takes place when
GDH is released from acutely damaged livers (Fig. 3D).
Validation of the ‘GDH-driven ammonia consumption’ in hepatocytes
The experiments described above suggest that high ammonia
concentrations in plasma leads to a ‘reverse’ GDH reaction, which
consumes rather than produces ammonia. To test whether this
‘GDH-driven ammonia consumption’ occurs not only in plasma
but also in cells, we used an in vitro system with primary mouse
hepatocytes incubated with ammonia in suspension (Fig. 4).
PDAC was used to inhibit GDH (Fig. 4A) in order to determine
its influence on ammonia metabolism. In hepatocytes isolated
from control mice, unphysiologically high ammonia concentra-
tions (2 mM) were required until PDAC caused a significant
increase of ammonia levels in the suspension buffer (Fig. 4B).
However, when hepatocytes from mice 24 h after CCl4 intoxica-
tion were used, PDAC treatment increased ammonia concentra-
tions in the suspension buffer, even with 0.5 mM ammonia.
Furthermore, in the absence of ammonia, hepatocytes secreted
a small but statistically significant amount of ammonia into the
buffer. Similarly, glutamate production was reduced by PDAC,Fig. 1. Evidence for a so far unrecognized mechanism of ammonia detoxification. (A)
and heart. ⁄p <0.05 compared to the corresponding controls (0 h). (C) Integrated meta
Supplementary data). Predicted ammonia concentrations in the liver outflow are higher c
the measured ammonia output. (D) Dose dependent experiment (10.9 to 1600 mg/kg
pattern at 132.4 mg/kg and higher doses, corresponding to the central necrotic lesio
pericentral CYP2E1 positive region which begins at 132.4 mg/kg with central necrosis stil
region was destroyed at the highest dose of 1600 mg/kg. The GS positive region was dest
GS activity (E), scale bars: 200 lm. ⁄p <0.05 when compared to the control group (0). (F) C
the experiment in (D); meas, in: analyzed concentrations in the portal vein (representin
meas. out: analyzed concentrations in the liver vein; sim. out: simulated concentrations in
of CCl4. ⁄⁄⁄p <0.001 and ⁄⁄p <0.01 compared to the measured ammonia output. (This figu
Journal of Hepatology 201an effect that was also stronger in hepatocytes isolated from
CCl4-exposed mice (Fig. 4C), which corresponds to the reverse
GDH reaction proposed in Fig. 3D (right panel). CCl4 destroys
the pericentral hepatocytes (Fig. 1D), which explains the reduced
glutamine generation by GS (Fig. 4D) and compromises urea cycle
enzymes (Supplementary Fig. 3B, C), which explains the reduced
urea production (Fig. 4E). Similar experiments were also per-
formed with cultivated (instead of suspended) hepatocytes from
untreated mice. The results demonstrate that inhibition of GDH
at high ammonia concentrations increases ammonia-induced
cytotoxicity (Supplementary Fig. 12B). These results show that
the catalytic direction of GDH reverses and clearly becomes
ammonia consuming also in hepatocytes in order to compensate
the compromised metabolism by urea cycle enzymes and GS
after intoxication.
Further evidence emerges from simulations with a set of novel
models 1–4 (Supplementary Fig. 11). If a reversible GDH reaction
was integrated into the hepatocyte compartment (Fig. 5A; Sup-
plementary Fig. 11), the discrepancy between in vivo measured
and simulated ammonia concentrations (Fig. 1C) completely dis-
appeared (Fig. 5B). The quantitative agreement was obtained
even without considering the blood compartment of the liver,
suggesting that after CCl4-induced damage, the ammonia con-
sumption catalyzed by GDH in the hepatocytes represents the
missing ammonia sink predicted by [4].
Therapy of hyperammonemia based on the reverse GDH reaction
The above described ammonia consumption catalyzed by the
GDH reaction (Figs. 3B–D and 4) and the aforementioned
decrease in plasma a-KG levels (Fig. 3A) prompted us to test
whether supplementation of a-KG in mice helps to detoxify
ammonia. Therefore, mice received a hepatotoxic dose of CCl4
(1.6 g/kg) and 24 h later a-KG (280 mg/kg) was injected into
the tail vein. Blood was collected immediately before as well as
15, 30 and 60 min after injection of a-KG. A decrease in plasma
ammonia concentrations by 31, 40 and 43% was observed 15,
30 and 60 min after a-KG injection, respectively (Fig. 6A). Gluta-
mate increased after 15 min and decreased again after longer
periods probably due to the consumption by further metabolism.
a-KG transiently increased in plasma after injection and then
rapidly decreased. Analysis of GDH activity demonstrated that
the experiment was performed under conditions of high plasma
activity. In control mice, injection of a-KG did not alter blood
concentrations of ammonia or glutamate (Fig. 6B). In addition,
plasma a-KG levels were lower in CCl4-treated mice compared
to the control mice, suggesting increased consumption in mice
with damaged livers.Experimental design. (B) Ammonia concentrations in the portal vein, hepatic vein
bolic spatio-temporal model using the technique described by [4] (video in the
ompared to the experimental data. ⁄⁄⁄p <0.001, ⁄⁄p <0.01 and ⁄p <0.05 compared to
CCl4 24 h after administration) showing macroscopic alterations with a spotted
n in hematoxylin/eosin (H&E) staining, scale bars: 100 lm. Destruction of the
l surrounded by CYP2E1 positive surviving hepatocytes; the entire CYP2E1 positive
royed only at 132.4 mg/kg and higher doses, which corresponds to the decrease in
omparison of analyzed and simulated ammonia concentrations in the liver vein for
g 85% of the liver inflow) and heart blood (representing 15% of the liver inflow);
the liver vein. Data are mean values and SD of three mice per time point and dose
re appears in colour on the web.)
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hepatocytes, GDH generates ammonia, which is detoxified by the urea cycle. In pericentral hepatocytes, GDH generates glutamate which is required as a substrate for the
GS reaction to form glutamine (Gln). Biosynthesis of a-KG takes place in the periportal hepatocytes; a-KG is then partially exported and taken up again by the pericentral
hepatocytes, where it is needed for GS [25,26]. After induction of liver damage, the expression of urea cycle enzymes decreased and the pericentral region with GS is
completely destroyed. This leads to increased blood ammonia concentrations. However, also GDH is released from damaged hepatocytes and catalyzes a reaction in blood
consuming ammonia and a-KG to generate glutamate (Glu). This reaction can go until a-KG in blood is consumed. In this situation a-KG and NADPH should be
therapeutically substituted. (This figure appears in colour on the web.)
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Research ArticleIn the aforementioned experiment, the molar amount of glu-
tamate produced in the damaged liver after a-KG injection was
higher than ammonia consumption (Fig. 6A). Therefore, the
results cannot only be explained by the reverse GDH reaction,
but may be due to the consumption of a-KG by transaminases
that contribute to the generation of glutamate. Indeed, tail vein
injection of the transaminases inhibitor AOA prior to a-KG injec-
tion reduced the production of glutamate (Fig. 6C) and improved
ammonia detoxification. The efficiency of transaminases inhibi-
tion by AOA in vivo has been confirmed in preliminary experi-
ments (Supplementary Figs. 13 and 14).
The reverse GDH reaction requires NADPH as a cofactor; how-
ever, NADPH concentrations are very low in blood. To determine
how NADPH levels are altered in our model of liver damage, both
NADPH and its oxidized form NADP+ were analyzed. Blood866 Journal of Hepatology 201concentrations of both NADPH and NADP+ increased after induc-
tion of liver damage by CCl4 (Supplementary Fig. 15A). In addi-
tion, an enhanced NADP+/NADPH ratio was observed in both
blood and liver tissue (Supplementary Fig. 15B). This increase
in NADP+/NADPH ratio fits to a switch in the GDH reaction from
NADPH generation to NADPH consumption. Despite the increase
in NADPH after induction of liver damage, the concentrations are
still relatively low. Therefore, to study the influence of NADPH,
plasma from mice collected 24 h after CCl4 injection was incu-
bated with varying concentrations of NADPH in the presence of
NH4Cl (1 mM), a-KG (3 mM), AOA (1 mM) and GDH (12,000 U/L)
for one hour. A concentration dependent decrease in plasma
ammonia and an increase in glutamate were observed with
increasing concentrations of NADPH (Fig. 7A). A similar trend
for ammonia and glutamate was observed with increasing con-
centrations of a-KG and GDH (Fig. 7B, C). Moreover, addition of
AOA reduced both ammonia and glutamate concentrations (Sup-
plementary Fig. 16). To understand how the orientation of the
GDH reaction is controlled by ammonia and glutamate concen-
trations, titration experiments were performed, which indicated
that GDH significantly consumes ammonia beginning at concen-
trations of 150 lM and higher (Fig. 7D). In contrast, unphysiolog-
ically high concentrations of more than 10 mM glutamate were
required to block the reaction (Fig. 7E).
Based on these in vitro optimized concentrations, we designed
an in vivo study to treat hyperammonemia in mice. After the
induction of liver damage by CCl4, transaminases activities were
inhibited by AOA (13 mg/kg; tail vein injection; 24 h after CCl4
administration). Thirty minutes later a cocktail of a-KG
(280 mg/kg), GDH (720 U/kg) and NADPH (180 mg/kg) was intra-
venously injected. A dose of 280 mg/kg a-KG was chosen because6 vol. 64 j 860–871
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JOURNAL OF HEPATOLOGYit transiently normalized a-KG levels in mice 24 h after CCl4.
720 U/kg GDH was used because it resulted in plasma levels of
approximately 6000 U/L 15 min after injection (Supplementary
Fig. 17), an activity level shown to allow maximal ammonia con-
sumption in plasma in vitro (Fig. 7C). The dose of 180 mg/kg
NADPH was also considered as adequate in a pharmacokinetic
experiment (Supplementary Fig. 18) as it transiently increased
plasma NADPH to approximately 1.6 mM 2 min after injection.
Injection of the a-KG/GDH/NADPH cocktail (KGN cocktail)
reduced ammonia concentrations from 213 to 74 lM within
15 min after administration (Fig. 8). Simultaneously, glutamate
levels increased from 131 to 369 lM. Analysis of a-KG and
GDH activity in the plasma showed that substitution was suc-
cessful 15 min after the injection of the KGN cocktail. Moreover,
the activities of aspartate and alanine aminotransferase were suc-
cessfully inhibited by AOA. The mice were observed for three
weeks after the experiment and did not show any complications.Discussion
Guided by simulations with an IM predicting a missing ammonia
sink after severe CCl4-induced liver damage, we identified the
GDH reaction as fundamental for ammonia consumption, which
can be used therapeutically by the administration of a cocktail
of GDH and cofactors.Journal of Hepatology 201Therapy for hyperammonemia remains challenging [8–10].
Hemodialysis is the most efficient treatment for reducing ele-
vated blood ammonia concentrations [11,12]. For milder forms
of hyperammonemia, pharmacologic management is possible
[13]. Efficient strategies for patients with urea cycle defects
include infusion of phenylacetate or benzoate. Phenylacetate
combines with glutamine to form a product which can be
excreted by the kidneys [9,13,14]. Conversely, benzoate combines
with glycine to form hippurate, which is also excreted in urine
[13,15]. Both compounds reduce the total body nitrogen content;
however, this therapy has also failed in a fraction of patients with
hyperammonemic crisis who became refractory most probably
due to the accumulation of nitrogen waste [9]. This led to the
concept that only blood ammonia concentrations below 500 lM
should be treated pharmacologically; whereas, more severe
hyperammonemia requires aggressive interventions with renal
replacement therapies, such as hemodialysis [12,16]. In such sit-
uations with either severe or refractory hyperammonemia the
therapeutic strategy developed in the present study may be an
alternative to hemodialysis.
The current experiments demonstrate that infusion of a KGN-
cocktail reduces ammonia close to normal levels within minutes.
Under these conditions, a GDH-catalyzed reaction takes place in
blood where ammonia and a-KG are consumed to form gluta-
mate in an NADPH-dependent reaction. GDH was also previously
reported to switch its catalytic orientation under physiological6 vol. 64 j 860–871 867
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Research Articleconditions. In the periportal compartment of the liver lobule,
GDH generates ammonia (Fig. 3D), which fuels the urea cycle.
In the pericentral compartment, GDH is known to consume
ammonia to generate glutamate for the GS reaction [17–19].
The present study shows by use of a GDH inhibitor that GDH
released from damaged liver tissue may catalyze an ammonia
consuming reaction under conditions of hyperammonemia. By
releasing GDH from damaged hepatocytes into the blood, the868 Journal of Hepatology 201damaged liver provides a mechanism that reduces blood ammo-
nia levels. However, this protective mechanism is limited by the
availability of the GDH substrate, a-KG. The present study shows
that a-KG strongly decreases upon induction of acute liver dam-
age, because it is consumed by the reverse GDH reaction. This
prompted us to supplement a-KG, increase blood concentrations
of NADPH, and infuse GDH. Indeed, the combined injection of
a-KG, GDH and NADPH efficiently reduced blood ammonia6 vol. 64 j 860–871
050
100
520
Am
m
on
ia
 (μ
M
)
150
200
***
0
200
400
600
G
lu
ta
m
at
e 
(μ
M
)
***
- - +
- + +
KGN-cocktail
AOA
0
300
600
900
1200
α-
Ke
to
gl
ut
ar
at
e 
(μ
M
)
Time after KGN
injection (min)
*
-30 0 15
0
2000
4000
8000
AS
T 
(U
/L
)
6000
***
***
0
4000
8000
16,000
12,000
AL
T 
(U
/L
)
**
- - +
- + +
KGN-cocktail
AOA
0
2000
4000
6000
G
D
H
 a
ct
iv
ity
 (U
/L
)
Time after KGN
injection (min)
***
-30 0 15
Fig. 8. Treatment of hyperammonemia by injection of a cocktail of GDH and
optimized cofactor doses. A cocktail of GDH (720 U/kg), a-KG (280 mg/kg) and
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the KGN cocktail reduced ammonia and increased glutamate concentrations in
the blood of mice. a-KG and GDH activity increased while aspartate (AST) and
alanine aminotransferase (ALT) activities decreased. Data are mean values and SD
of four mice treated at different experimental days with individually prepared
therapeutic cocktails. ⁄⁄⁄p <0.001, ⁄⁄p <0.01 and ⁄p <0.05 when compared to the
control group (30).
JOURNAL OF HEPATOLOGYconcentrations. A GDH bolus was injected to result in plasma
peak concentrations between 5000 and 6000 U/L. This is in the
same order of magnitude as observed in patients after acetamino-
phen intoxication [20]. Therefore, in patients with acute liver
intoxication with high blood GDH, therapy with a-KG and
NADPH might be sufficient. However, it should be considered
that the GDH reaction in blood described here (Fig. 3D) does
not explain all experimental observations: a-KG decreases signif-
icantly 12 h after CCl4 administration when there is no significant
increase in blood GDH (Fig. 3A). This discrepancy may be
explained by the intracellular change of the catalytic direction
of GDH in the periportal hepatocytes, which may precede the
GDH release into the blood. However, this was not further ana-
lyzed in the present study as we choose to focus on the therapeu-
tically more relevant GDH reaction taking place in blood.
a-KG was previously tested for the treatment of hyperam-
monemia between 1964 and 1978 [21,22], but this strategyJournal of Hepatology 201was abandoned because it was not sufficiently efficient for clini-
cal application. The reverse GDH reaction in the blood and its
requirement for NADPH as a cofactor was not yet known when
the early therapeutic studies with a-KG were performed. In addi-
tion, injection of a-KG alone in the present study resulted in only
a relatively weak reduction of hyperammonemia. This reduction
may be possible because in addition to GDH, NADPH is also
released from deteriorating hepatocytes after CCl4 injection.
The concept of treating hyperammonemia by a-KG/GDH/
NADPH infusion originates from simulations using an integrated
metabolic spatio-temporal model [4]. This model is based on
well-understood pathways of ammonia detoxification, such as
urea cycle enzymes and the GS reaction [23,24]. It predicted
higher ammonia concentrations compared to the measured data.
Therefore, we analyzed liver tissue during the damage induction
and regeneration processes, but the results could also not explain
the discrepancy. Time-resolved gene array experiments following
CCl4 injection led to the observation that a general decrease in
metabolizing enzymes occurs including enzymes involved in
ammonia metabolism. All enzymes of the urea cycle were tran-
scriptionally downregulated by at least 60%. Factors identified
by the gene array analysis were further analyzed by activity
assays and immunostaining. Key observations were: (a) the GS
positive region, which is initially completely destroyed by CCl4,
shows a delayed recovery and does not return to normal levels
before day 12; and (b) CPS1, the rate limiting enzyme in the urea
cycle normally expressed in the periportal region, is downregu-
lated during the destruction process (days 1–3), but its expres-
sion then extends throughout the entire liver lobule during
days 4–6. The other urea cycle enzymes showed a similar time
course as CPS1 with the exception of arginase1, which decreased
only slightly during the destruction and regeneration process.
Glutaminase showed a similar time course and pattern as CPS1.
Nevertheless, none of these alterations could explain the
observed discrepancy. However, the refined models that take into
account the reversible GDH reaction show an excellent agree-
ment with the experimental data suggesting that consumption
by the GDH reaction represents the previously predicted ammo-
nia sink, hence providing an example for model guided
experimentation.
In conclusion, a novel form of therapy has been identified that
allows the rapid correction of hyperammonemia by the infusion
of a-KG, GDH and NADPH. This pharmacotherapy may prove rel-
evant as an emergency therapy for episodes of hyperammonemia
in urea cycle disease or liver cirrhosis.Financial support
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